Table 3.

Endoscopic Changes Post-taVNS Therapy: Retrospective Review

Study Subject	Diagnosis	Disease location	Pre-study Endoscopic disease severity	Medication at study entry	Duration of taVNS (weeks)	Follow up endoscopic disease severity	Clinical outcome
6	CD	Right colon	SES-CD = 4	None	69	SES-CD = 3	Continued taVNS started UST
7	CD	Left colon	SES-CD = 6	Mesalamine	60	SES-CD = 2	Continued taVNS
8	CD	Left colon	SES-CD = 10	VDZ	16	SES-CD = 4	Continued taVNS
9	UC	Pancolonic	Mayo score 2	Mesalamine	21	Mayo score 2	Discontinued taVNS started VDZ

SES-CD Simple Endoscopic Severity of Crohn’s disease

UST Ustekinumab

VDZ Vedolizumab